Sustained Fibrinolysis After Administration of t-PA Despite Its Short Half-Life in the Circulation

Summary

To characterize the duration of the fibrinolytic response to tissue-type plasminogen activator (t-PA) and streptokinase (SK) in patients with acute myocardial infarction we serially assayed crosslinked fibrin degradation products (XL-FDP) and Bβ15-42 fibrinopeptide. Use of specific monoclonal antibodies permitted quantification and differentiation of fibrin from fibrinogen degradation products. Marked elevations of XL-FDP occurred within 1 hour after administration of t-PA (n = 13) or SK (n = 35) to >1000 ng/ml in 79% of the patients. All patients given t-PA exhibited elevations of XL-FDP >1000 ng/ml, most exhibited values >5000 ng/ml (79% of patients). In contrast 6 of the patients given SK failed to exhibit XL-FDP >1000 ng/ml. XL-FDP >5000 ng/ml occurred in only 14%. The difference in the response to t-PA compared to SK was particularly striking 7 hours or more after administration of activator at which time XL-FDP were markedly elevated in patients given t-PA (5821 ± 1683 ng/ ml) compared with decreasing values in patients given SK (2924 ± 1186 ng/ml) (p <0.01). Levels of Bβ315-42 were significantly higher after t-PA compared with SK beginning 3 hours after treatment, consistent with a greater intensity of fibrinolytic response to t-PA. Marked elevations of this short lived degradation product of fibrin (t_1/2 = 10-20 minutes) in the samples drawn late after administration of t-PA (44.3 ±12.8 nM) but not after SK (11.7 ± 4.5 nM) confirmed prolonged fibrinolytic activity of plasmin after t-PA. There was no discernible relationship between the extent of fibrinolysis as assessed by XL-FDP and Bβ 15-42 and the total dose of t-PA administered or the duration of the infusion. Elevations of XL-FDP invariably occurred after SK, and were not significantly different in patients with or without recanalization. Thus “clinical success” of coronary thrombolysis appears to depend on a favorable balance between thrombosis and fibrinolysis rather than the intensity of fibrinolysis alone. The prolonged fibrinolytic activity after t-PA appears to reflect the enhanced binding of this activator to fibrin and is likely to result in more sustained and hence more effective fibrinolysis with t-PA compared to SK despite the short half-life of t-PA (t_1/2 = 6 minutes) in the circulation.

Keywords

Thrombolysis - Fibrin degradation products - Fibrinopep-tides - Myocardial infarction

• References

• 1 Shafer KE, Santoro SA, Sobel BE, Jaffe AS. Monitoring activity of fibrinolytic agents. A therapeutic challenge. Am J Med 1984; 76: 879-886
• 2 Burket MW, Smith MR, Walsh TE, Brewster PS, Fraker TD. Relation of effectiveness of intracoronary thrombolysis in acute myocardial infarction to systemic lytic state. Am J Card 1985; 56: 441-444
• 3 Lew AS, Cercek B, Laramee P, Hod H, Shah PK, Ganz W. The time interval from initiation of IV streptokinase is directly related to the residual fibrinogen level and is shortened by pretreatment with heparin. J Am Coll Card 1986; 7: 17 (A)
• 4 Eisenberg PR, Sherman L, Rich M, Schwartz D, Schechtman K, Geltman E, Sobel BE, Jaffe AS. Importance of continued activation of thrombin reflected by fibrinopeptide A to the efficacy of thrombolysis. J Am Coll Card 1986; 7: 1255-1262
• 5 Eisenberg PR, Sobel BE, Sherman LA, Perez JP, Jaffe AS. The prognostic implications of elevated fibrin specific cross-linked products after infarction - a marker of intense endogenous thrombosis and thrombolysis. J Am Coll Card 1986; 116 (A)
• 6 Rylatt DB, Blake AS, Cottis LE. et al. An immunoassay for human D dimer using monoclonal antibodies. Thrornb Res 1983; 31: 767-778
• 7 Elms MJ, Bunce IH, Bundesen PG, Rylatt DB, Webber AJ, Masci PP, Whitaker AN. Measurement of crosslinked fibrin degradation products - an immunoassay using monoclonal antibodies. Thromb Haemost 1983; 50: 591-594
• 8 Kudryk B, Rohoza A, Ahadi M, Chin J, Wiebe ME. Specificity of a monoclonal antibody for the NH₂-terminal region of fibrin. Mol Immun 1983; 20: 1191-1200
• 9 Niewenhuizen W, Erneis JJ, Vermond A. Catabolism of purified rat fibrin(ogen) plasrnin degradation products in rats. Thrornb Res 1975; 48: 59-61
• 10 Eisenberg PR, Sherman LA, Schectrnan LA, Sobel BE, Jaffe AS, Fibrinopeptide A. A marker of acute coronary thrombosis. Circulation 1985; 71: 912-918
• 11 Henry PD, Roberts R, Sobel BE. Rapid separation of creatine phosphokinase isoenzymes by batch adsorbtion with glass beads. Clin Chern 1975; 21: 844-849
• 12 Verstraete M, Bounarneaux H, de Cock F, Van de Werf F, Collen D. Pharmacokinetics and systemic fibrinogenolytic effects of recombinant human tissue-type plasminogen activator (rt-PA) in humans. J Pharm Exp Therapeut 1985; 235: 506-512
• 13 Holvoet P, Lijnen HR, Collen D. A monoclonal antibody preventing binding of tissue-type plasminogen activator to fibrin: Useful to monitor fibrinogen breakdown during t-PA infusion. Blood 1986; 67: 1482-1487
• 14 Hoylaerts M, Rijken DC, Lijnen HR, Collen D. Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. J Biol Chem 1982; 257: 2912-2919
• 15 Wiman B, Collen D. On the kinetics of the reaction between human antiplasmin and plasmin. Eur J Biochem 1978; 84: 573-578
• 16 Camiolo SM, Thorsen S, Astrup T. Fibrinogenolysis and Fibrinolysis with tissue plasminogen activator, urokinase, streptokinase-activated human globulin, and plasmin. Proc Soc Exp Biol Med 1971; 138: 277-280
• 17 Wohl RC, Summaria L, Arzadon L, Robbins KC. Steady state kinetics of activation of human and bovine plasminogen by streptokinase and its molecular complexes with various activated forms of human plasminogen. J Biol Chem 1978; 253: 1402-1407
• 18 Pisano JJ, Finlayson JS, Peyton MP. Cross-link in fibrin polymerized by factor XIII: E-(y-glutamyl)lysine bonds. Science 1968; 160: 892-893
• 19 Francis CW, Marder VJ, Martin SE. Plasmic degradation of crosslinked fibrin I. Structural analysis of the particulate clot and identification of new macromolecular-soluble complexes. Blood 1981; 56: 456-464
• 20 Francis CW, Marder VJ, Barlow GH. Plasmic degradation of crosslinked fibrin, characterization of new macromolecular soluble complexes and a model of their structure. J Clin Invest 1980; 66: 1033-1043
• 21 Gaffney PJ, Brasher M. Subunit structure of the plasmin induced degradation products of crosslinked fibrin. Biochem Biophys Acta 1973; 295: 308-313
• 22 Gaffney PJ, Lane DA, Kakkar VV, Brasher M. Characterization of a soluble D dimer - E complex in crosslinked fibrin digests. Thromb Res 1975; 7: 89-99
• 23 Morio M, Aoki N. Isolation and characterization of α₂-plasmin inhibitor from human plasma. Eur J Biochem 1976; 251: 5956-5965
• 24 Gonias SL, Einarson M, Pizzo SV. Catabolic pathways for streptokinase activator complex in mice. J Clin Invest 1982; 70: 412-423
• 25 Agnelli G, Buchanon MR, Fernandez F, Van Ryn J, Hirsh J. Sustained thrombolysis with DNA-recombinant tissue type plasminogen activator in rabbits. Blood 1985; 66: 399-401
• 26 Gold HK, Leinbach RC, Garabedian HD. et al. Acute coronary reocclusion after thrombolysis with recombinant human tissue-type plasminogen activator: prevention with a maintenance infusion. Circulation 1986; 73: 347-352
• 27 Brown BG, Gallery CA, Badger RS, Kennedy JW, Mathey D, Bolson EL, Dodge HT. Incomplete lysis of thrombus in the moderate underlying atherosclerotic lesion during intracoronary infusion of streptokinase for acute myocardial infarction: quantitative angiographic observations. Circulation 1986; 73: 653-661
• 28 Fox K AA, Robison AK, Knabb RM, Rosamond TL, Sobel BE, Bergmann SR. Prevention of coronary thrombosis with subthrombolytic doses of tissue type plasminogen activator. Circulation 1985; 72: 1346-1354
• 29 Zammarron C, Lijnen HR, Collen D. Influence of exogenous and endogenous tissue-type plasminogen activator on the lysability of clots in a plasma milieu in vitro. Thromb Res 1984; 35: 335-345
• 30 Hamstein A, Wiman B, de Faire U, Blomback M. Increased plasma levels of a rapid inhibitor of tissue type plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985; 31: 767-778
• 31 Walker ID, Davidson JF, Hutton I, Lawrie T DV. Disordered “fibrinolytic potential” in coronary heart disease. Thromb Res 1977; 20: 509-520
• 32 Franzen J, Nilsson B, Johansson BW, Nilsson IM. Fibrinolytic activity in men with acute myocardial infarction before 60 years of age. Acta Med Scan 1983; 214: 339-344
• 33 Estelles A, Tormao G, Azner J, Espana F, Tormo V. Reduced fibrinolytic activity in coronary heart disease in basal conditions and after exercise. Thromb Res 1985; 40: 373-383